These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34320250)

  • 1. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
    Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
    Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
    Vickery BP; Vereda A; Nilsson C; du Toit G; Shreffler WG; Burks AW; Jones SM; Fernández-Rivas M; Blümchen K; O'B Hourihane J; Beyer K; Anagnostou A; Assa'ad AH; Ben-Shoshan M; Bird JA; Carr TF; Carr WW; Casale TB; Chong HJ; Ciaccio CE; Dorsey MJ; Fineman SM; Fritz SB; Greiner AN; Greos LS; Hampel FC; Ibáñez MD; Jeong DK; Johnston DT; Kachru R; Kim EH; Lanser BJ; Leonard SA; Maier MC; Mansfield LE; Muraro A; Ohayon JA; Oude Elberink JNG; Petroni DH; Pongracic JA; Portnoy JM; Rachid R; Rupp NT; Sanders GM; Sharma HP; Sharma V; Sher ER; Sher L; Sindher SB; Siri D; Spergel JM; Sprikkelman AB; Sussman GL; Tsoumani M; Varshney P; Vitalpur G; Wang J; Yang WH; Zubeldia JM; Smith A; Ryan R; Adelman DC
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1879-1889.e13. PubMed ID: 33359589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials.
    Blumchen K; Kleinheinz A; Klimek L; Beyer K; Anagnostou A; Vogelberg C; Butovas S; Ryan R; Norval D; Zeitler S; Du Toit G
    Allergy Asthma Clin Immunol; 2023 Mar; 19(1):21. PubMed ID: 36915184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
    Brown KR; Baker J; Vereda A; Beyer K; Burks AW; du Toit G; O'B Hourihane J; Jones SM; Norval D; Dana A; Shreffler W; Vickery BP; Casale T; Skeel B; Adelman D
    J Allergy Clin Immunol; 2022 Jun; 149(6):2043-2052.e9. PubMed ID: 34971646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peanut (
    Casale TB; Irani AM
    Expert Rev Clin Immunol; 2023 Mar; 19(3):253-265. PubMed ID: 36524617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
    Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernández-Rivas M; Hourihane JO; Krawiec M; Lieberman J; Scurlock AM; Vickery BP; Smith A; Tilles SA; Adelman DC; Brown KR;
    Ann Allergy Asthma Immunol; 2022 Dec; 129(6):758-768.e4. PubMed ID: 35973655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy.
    Yu S; Smith A; Hass S; Wu E; Chai X; Zhou J; Ayyagari R; Liu JS; Robison D; Donelson SM; Tilles S
    Adv Ther; 2021 Aug; 38(8):4321-4332. PubMed ID: 34236672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AR101 Oral Immunotherapy for Peanut Allergy.
    ; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
    N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
    Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW;
    J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age.
    Du Toit G; Brown KR; Vereda A; Irani AM; Tilles S; Ratnayake A; Jones SM; Vickery BP
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300145. PubMed ID: 38320526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Children and caregiver proxy quality of life from peanut oral immunotherapy trials.
    Galvin AD; Vereda A; Rodríguez del Río P; Muraro A; Jones C; Ryan R; Norval D; Jobrack J; Anagnostou A; Wang J
    Clin Transl Allergy; 2022 Dec; 12(12):e12213. PubMed ID: 36573312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
    DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp.
    Portnoy J; Shroba J; Tilles S; Romdhani H; Donelson SM; Latremouille-Viau D; Bungay R; Chen K; McCann W
    Ann Allergy Asthma Immunol; 2023 May; 130(5):649-656.e4. PubMed ID: 36738781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
    Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.
    Kim EH; Bird JA; Keet CA; Virkud YV; Herlihy L; Ye P; Smeekens JM; Guo R; Yue X; Penumarti A; Qaqish B; Li Q; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2024 Jan; 153(1):173-181.e10. PubMed ID: 37815782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.